Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?

Nature Clinical Practice Oncology volume 3, pages 294–295 (2006)Cite this article

boxed-textSchuette W et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23: 8389–8395

To be an accepted standard treatment for non-small-cell lung cancer, docetaxel needs additional comparisons in randomized trials

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Shepherd FA et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095–2103

    Article  CAS  Google Scholar 

  2. Hanna N et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597

    Article  CAS  Google Scholar 

  3. Shepherd F et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Article  CAS  Google Scholar 

  4. Gridelli C et al. (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer:the DISTAL 01 study. Br J Cancer 91: 1996–2004

    Article  CAS  Google Scholar 

  5. Camps C et al. (2005) Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 3: 467–472

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Clinical and Biological Sciences, Professor of Respiratory Medicine, at the University of Turin, and Director of the Thoracic Oncology Unit at S Luigi Hospital, Orbassano, Turin, Italy

    Giorgio V Scagliotti

Authors
  1. Giorgio V Scagliotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giorgio V Scagliotti.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scagliotti, G. Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?. Nat Rev Clin Oncol 3, 294–295 (2006). https://doi.org/10.1038/ncponc0510

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0510

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing